Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

intervet ireland limited - live attenuated avian rhinotracheitis virus strain trt 11/94 - lyophilisate for suspension for spray - . - avian rhinotracheitis virus - chickens - immunological - live vaccine

Iisrael - inglise - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - live attenuated oka/merck strain of varicella-zoster virus - powder and solvent for suspension for injection - live attenuated oka/merck strain of varicella-zoster virus 19400 pfu / 0.65 ml - zoster, live attenuated - zoster, live attenuated - zostavax is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older.

Suurbritannia - inglise - VMD (Veterinary Medicines Directorate)

ceva animal health ltd - avian pneumovirus - lyophilisate for oculonasal suspension - live viral vaccine - chickens

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

ceva santé animale - live attenuated infectious bronchitis (ib) virus, strain 1/96, variant subtype - lyophilisate for suspension - min. 2.8 per cent - avian infectious bronchitis virus vaccine - fowl - chicken - immunological - live vaccine

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

ceva santé animale - live attenuated infectious bronchitis (ib) virus, strain 1/96, variant subtype - lyophilisate for oculonasal suspension/use in drinking water - . - avian infectious bronchitis virus - chickens - immunological - live vaccine

Euroopa Liit - inglise - EMA (European Medicines Agency)

laboratorios hipra s.a - live ge- tk- double-gene-deleted bovine herpes virus type 1, strain ceddel: 106.3–107.3 ccid50 - immunologicals - cattle - for the active immunisation of cattle from three months of age against bovine herpes virus type 1 (bohv-1) to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.onset of immunity: 21 days after completion of the basic vaccination scheme.duration of immunity: 6 months after completion of the basic vaccination scheme

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

intervet ireland limited - live newcastle disease virus clone 30 - lyophilisate for oculonasal suspension/use in drinking water - . - newcastle disease virus / paramyxovirus - chickens, turkeys - immunological - live vaccine

Austraalia - inglise - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - live aroa-gene deleted escherichia coli,type o78,ec34195 - unknown - live aroa-gene deleted escherichia coli,type o78,ec34195 vaccine-microbial active 0.0 - active constituent

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg; leucine, quantity: 0.432 mg - injection, powder for - excipient ingredients: lactose; sorbitol; mannitol; threonine; serine; proline; glycine; alanine; valine; methionine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - live varicella vaccine, quantity: 4000 pfu/ml; isoleucine, quantity: 0.355 mg - injection, powder for - excipient ingredients: lactose; mannitol; sorbitol; threonine; serine; proline; glycine; alanine; valine; methionine; leucine; tyrosine; phenylalanine; tryptophan; lysine hydrochloride; histidine; arginine - varilrix hsa-free is indicated for active immunisation against varicella of healthy subjects from 9 months of age. groups who would particularly benefit from vaccination include: non-immune adults, especially those in at-risk occupations such as health care workers, teachers and workers in children's day-care centres. non-immune parents of young children. non-immune household contacts, both adults and children, of immunocompromised patients with no history of the disease.